



Recent Advances of Protein Therapeutics

Guest Editor:

Dr. Zhilei Chen

Microbial Pathogenesis and Immunology, Texas A and M Health Science Center, Bryan, TX, USA

Deadline for manuscript submissions:

closed (20 September 2023)

Message from the Guest Editor

Protein-based therapeutics have recently evolved into a large class of drug molecules that encompass both natural and engineered recombinant proteins. Proteins exhibit unique advantages and limitations as therapeutics. This Special Issue will focus on the development of protein therapeutics against new drug targets, as well as technologies for protein therapeutic engineering.

1. Antibodies and synthetic biotherapeutic engineering;
2. Purification and industrial production of therapeutic proteins;
3. Formulation of and delivery technologies for protein therapeutics;
4. New display technologies for therapeutic protein engineering;
5. Evolvability and developability of antibodies and synthetic scaffolds;
6. Protein–drug conjugates;
7. Computational protein design and engineering;
8. Natural and synthetic protein scaffold engineering.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical
Engineering, Texas A&M
University, College Station, TX
77843, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

Journal Rank: JCR - Q2 (*Engineering, Biomedical*)

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2024).

Contact Us

Bioengineering Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/bioengineering
bioengineering@mdpi.com
[X@Bioeng_MDPI](https://twitter.com/Bioeng_MDPI)